0000000001130639

AUTHOR

B. Tettenborn

showing 3 related works from this author

„Phobischer Schwankschwindel”

1997

Due to the results of an interdisciplinary study on patients with vertigo as the chief symptom and on the background of psychodynamic theories concerning anxiety disorders the term of phobic postural vertigo (Brandt & Dieterich 1986) is discussed. It becomes obvious that phobic postural vertigo is a generalizing term which encompasses different forms of psychogenic vertigo. The authors plead for a more differentiated diagnosis and subgroup oriented classification of vertigo caused by psychiatric disorders.

medicine.medical_specialtyNeurologybiologybusiness.industryPsychosomatic medicineGeneral Medicinemedicine.diseasebiology.organism_classificationPhobic disorderPsychiatry and Mental healthPhysical medicine and rehabilitationNeurologyVertigomental disordersotorhinolaryngologic diseasesmedicinePostural BalanceAnxietysense organsNeurology (clinical)Neurosurgerymedicine.symptombusinessAgoraphobiaDer Nervenarzt
researchProduct

Multifocal Ischemic Brain-Stem Lesions

1993

The clinical symptoms and signs of brain-stem ischemia are far less well defined than in ischemia due to carotid or middle cerebral artery disease. They consist of many different syndromes, and it is often difficult to correlate the clinical findings with a single functional or morphological lesion within the brain-stem.

Pathologymedicine.medical_specialtybusiness.industryVertebral arteryMultiple sclerosisIschemiaDiseasemedicine.diseaseLesionPosterior inferior cerebellar arteryIschemic brainmedicine.arteryMiddle cerebral arterymedicinecardiovascular diseasesmedicine.symptombusiness
researchProduct

Oxcarbazepine does not affect the anticoagulant activity of warfarin.

1992

The possible interaction of the antiepileptic drug oxcarbazepine (OCBZ) on the anticoagulant effect of warfarin was investigated in 10 healthy male volunteers. After reaching steady-state conditions by repeated administration of warfarin, the prothrombin time (Quick value) was assessed before and after single (600 mg) and multiple dosing (450 mg twice daily in 1 week) of OCBZ. In 7 of the 10 volunteers with evaluable data, the prothrombin time was not significantly different (paired t test) from baseline either after single (p = 0.299) or repeated dosing (p = 0.333), indicating that OCBZ does not interact to any relevant extent with the hypothrombinemic effect of warfarin.

DrugAdultMalemedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentOxcarbazepinePharmacologymedicineHumansDrug InteractionsOxcarbazepineBlood Coagulationmedia_commonProthrombin timeChemotherapymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryAnticoagulantWarfarinDose–response relationshipAnticonvulsantCarbamazepineNeurologyAnesthesiaProthrombin TimeAnticonvulsantsNeurology (clinical)Warfarinbusinessmedicine.drugEpilepsia
researchProduct